These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9167416)

  • 1. A cerebrospinal fluid turnover in Parkinson's disease.
    Jamrozik Z; Królicki L; Kwieciński H; Florek M
    Mater Med Pol; 1996; 28(3):79-82. PubMed ID: 9167416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRI atrophy parameters related to cognitive and motor impairment in Parkinson's disease.
    Alegret M; Junqué C; Pueyo R; Valldeoriola F; Vendrell P; Tolosa E; Mercader JM
    Neurologia; 2001 Feb; 16(2):63-9. PubMed ID: 11257931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlations between gray matter reductions and cognitive deficits in dementia with Lewy Bodies and Parkinson's disease with dementia.
    Sanchez-Castaneda C; Rene R; Ramirez-Ruiz B; Campdelacreu J; Gascon J; Falcon C; Calopa M; Jauma S; Juncadella M; Junque C
    Mov Disord; 2009 Sep; 24(12):1740-6. PubMed ID: 19569130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study.
    Aarsland D; Brønnick K; Larsen JP; Tysnes OB; Alves G;
    Neurology; 2009 Mar; 72(13):1121-6. PubMed ID: 19020293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive decline correlates with neuropathological stage in Parkinson's disease.
    Braak H; Rüb U; Del Tredici K
    J Neurol Sci; 2006 Oct; 248(1-2):255-8. PubMed ID: 16814807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive status correlates with neuropathologic stage in Parkinson disease.
    Braak H; Rüb U; Jansen Steur EN; Del Tredici K; de Vos RA
    Neurology; 2005 Apr; 64(8):1404-10. PubMed ID: 15851731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive characteristics associated with mild cognitive impairment in Parkinson's disease.
    McKinlay A; Grace RC; Dalrymple-Alford JC; Roger D
    Dement Geriatr Cogn Disord; 2009; 28(2):121-9. PubMed ID: 19690414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cognition deterioration in Parkinson's disease: associated risk factors].
    Errea JM; Ara JR
    Rev Neurol; 1999 Mar 1-15; 28(5):439-43. PubMed ID: 10229953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy.
    Cordato NJ; Duggins AJ; Halliday GM; Morris JG; Pantelis C
    Brain; 2005 Jun; 128(Pt 6):1259-66. PubMed ID: 15843423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
    Holmberg B; Rosengren L; Karlsson JE; Johnels B
    Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain-derived neurotrophic factor concentrations in the cerebrospinal fluid of patients with Parkinson's disease.
    Salehi Z; Mashayekhi F
    J Clin Neurosci; 2009 Jan; 16(1):90-3. PubMed ID: 19017558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls.
    Burton EJ; McKeith IG; Burn DJ; Williams ED; O'Brien JT
    Brain; 2004 Apr; 127(Pt 4):791-800. PubMed ID: 14749292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's disease is associated with hippocampal atrophy.
    Camicioli R; Moore MM; Kinney A; Corbridge E; Glassberg K; Kaye JA
    Mov Disord; 2003 Jul; 18(7):784-90. PubMed ID: 12815657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease.
    Dalaker TO; Larsen JP; Dwyer MG; Aarsland D; Beyer MK; Alves G; Bronnick K; Tysnes OB; Zivadinov R
    Neuroimage; 2009 Oct; 47(4):2083-9. PubMed ID: 19539037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study.
    Rodriguez-Oroz MC; Lage PM; Sanchez-Mut J; Lamet I; Pagonabarraga J; Toledo JB; García-Garcia D; Clavero P; Samaranch L; Irurzun C; Matsubara JM; Irigoien J; Bescos E; Kulisevsky J; Pérez-Tur J; Obeso JA
    Mov Disord; 2009 Jul; 24(10):1437-44. PubMed ID: 19452554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy.
    Holmberg B; Johnels B; Blennow K; Rosengren L
    Mov Disord; 2003 Feb; 18(2):186-90. PubMed ID: 12539213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study on neurochemistry of cerebrospinal fluid in advanced Parkinson's disease.
    Liu H; Iacono RP; Schoonenberg T; Kuniyoshi S; Buchholz J
    Neurobiol Dis; 1999 Feb; 6(1):35-42. PubMed ID: 10078971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases.
    Yin GN; Lee HW; Cho JY; Suk K
    Brain Res; 2009 Apr; 1265():158-70. PubMed ID: 19368810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memory and executive function impairment predict dementia in Parkinson's disease.
    Levy G; Jacobs DM; Tang MX; Côté LJ; Louis ED; Alfaro B; Mejia H; Stern Y; Marder K
    Mov Disord; 2002 Nov; 17(6):1221-6. PubMed ID: 12465060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of differentially displayed proteins in cerebrospinal fluid of Parkinson's disease patients: a proteomic approach.
    Sinha A; Srivastava N; Singh S; Singh AK; Bhushan S; Shukla R; Singh MP
    Clin Chim Acta; 2009 Feb; 400(1-2):14-20. PubMed ID: 18977210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.